SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Zalicus Inc. Initiates the First of Two Phase 2a Studies with Z160, a First-in-Class, Oral, State-Dependent, Selective N-type Calcium Channel Blocker, for the Treatment of Chronic Neuropathic Pain